

**Immedica UK Limited / Neurocrine UK Limited - Methodological Note for HCP/ORDM/HCO disclosure 2025**

Data year: 2025

Year of publication: 2026

The company making this 2025 disclosure is known at the time of reporting in March 2026 as 'Immedica UK Limited'. Immedica UK Limited is a company registered in England and Wales. It changed its registered company name from Neurocrine UK Limited to Immedica UK Limited on 9 February 2026.

Throughout the data year 2025, the company now known as Immedica UK Limited was registered with the company name 'Neurocrine UK Limited', having previously changed its registered company name from Diurnal Limited to Neurocrine UK Limited on 21 October 2024. Throughout the data year 2025, Neurocrine UK Limited was part of the Neurocrine Biosciences group of companies, operating as a wholly owned subsidiary of Neurocrine Biosciences Inc. In January 2026, the parent company of the company now known as Immedica UK Limited was purchased by the Immedica Pharma group, after which the ultimate owner of the company now known as Immedica UK Limited is Immedica Pharma AB, a company registered in Sweden.

The disclosures for the data year 2025 made by the company now known as Immedica UK Limited will be reported in the company's previous name of 'Neurocrine UK Limited' as this was the name of the company for the duration of the data year 2025 and therefore the company name which the HCPs/ORDMs/HCOs subject of the disclosure would recognise.

**Contents**

<b>1</b>	<b>Definitions</b> .....	<b>2</b>
1.1	Recipients.....	2
1.2	Kind of ToVs .....	2
<b>2</b>	<b>Disclosure's Scope</b> .....	<b>3</b>
2.1	Products concerned.....	3
2.2	Company concerned.....	3
2.3	Excluded ToVs.....	3
2.4	ToVs date .....	3
2.5	Direct ToVs .....	3
2.6	Indirect ToVs.....	4
2.7	Non-monetary ToVs .....	5
2.8	ToVs in case of partial attendances or cancellation and refund.....	5
2.9	Cross-border activities .....	5

2.10	R&D.....	5
2.11	Voluntary disclosure.....	5
3	<b>Specific considerations</b> .....	5
3.1	Country unique identifier.....	5
3.2	Self-incorporated HCP .....	5
3.3	Multi-year agreements .....	6
3.4	Country specificities.....	6
3.5	Quality Checks .....	6
4	<b>Data protection legal basis</b> .....	6
4.1	Consent collection .....	6
4.2	Legitimate interests .....	6
5	<b>Form of disclosure</b> .....	6
5.1	Date of publication.....	6
5.2	Disclosure platform.....	6
5.3	Disclosure language.....	6
6	<b>Disclosure financial data</b> .....	6
6.1	Currency.....	6
6.2	VAT included or excluded .....	7
6.3	Calculation rules.....	7
7	<b>Additional Information</b> .....	7

## 1. Definitions

### 1.1. Recipients

Payments made during 2025 to UK and European entities were reviewed, and direct and indirect transfers of value to recipients under the ABPI 2024 Code of Practice and EFPIA codes were identified, as categorized in the recipients definitions and Transfers of Value Categories below:

- a. **Healthcare Professional (HCP):** A member of the medical, dental, pharmacy or nursing professions or any other person who, during his/her professional activities, may prescribe, purchase, supply, recommend or administer a Medicinal Product and whose primary practice, principal professional address or place of incorporation is in Europe.
- b. **Other Relevant Decision Makers (ORDMs):** Includes recipients with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not HCPs.
- c. **Healthcare Organization (HCO):** a healthcare, medical or scientific association or organization such as a hospital, clinic, foundation, university or other teaching institution or learned society whose business address, place of incorporation or primary place of operation is in Europe or through which one or more HCPs provide services

### 1.2. Kind of ToVs

A direct or indirect transfer of value, whether in cash, in kind or otherwise, in connection with the development or sale of medicines. A direct transfer of value is made directly by a company for the benefit of a recipient. Indirect transfers of value are those made on behalf of the company for the benefit of a Recipient, or those made through a Third Party and where Neurocrine UK Limited knows or can identify the Recipient that will benefit from the Transfer of Value.

## 2. Disclosure's Scope

### 2.1. Products concerned

Alkindi and Efmody

### 2.2. Company concerned

Immedica UK Limited, formerly known as Neurocrine UK Limited.

### 2.3. Excluded ToVs

Excluded ToVs are ToVs to Recipients in the European countries covered in the ABPI and EFPIA codes made by any other company in the Neurocrine Bioscience group, of which Neurocrine UK Limited is no longer a part.

### 2.4. ToVs date

The disclosure report includes transfers of value occurring between 1 January 2025 – 31 December 2025.

### 2.5. Direct ToVs

ABPI Transfer of Value Category	Example activities	HCP	HCO
<b>Donations and Grants (HCO Only):</b>  Provision of funds, benefits-in-kind or services freely given for the purpose of supporting healthcare, scientific research, or education with no consequent obligation on the recipient organisation, to provide goods or services to the benefit of Neurocrine UK Limited.	<ul style="list-style-type: none"><li>Charitable contributions</li><li>Business donations</li><li>Educational grants (e.g. fellowships, courses provided by an HCO)</li></ul>	N/A	YES
<b>Contributions to Cost of Event - Travel and accommodation relating to a congress or educational event:</b>  Reimbursement of HCP and HCO for payments covering travel, lodging, and related expenses for healthcare professionals attending meetings, conferences, or third-party educational/scientific meetings.	<ul style="list-style-type: none"><li>Travel (e.g. flight, train, taxi, car hires, tolls, mileage reimbursement, parking)</li><li>Accommodation</li></ul>	YES	YES
<b>Contributions to Cost of Event - Registration fees:</b>  TOVs related to the reimbursement of HCP and HCO for fees to register an HCP / HCO to attend a congress or educational event.	<ul style="list-style-type: none"><li>Registration fees paid for the HCP/HCO to attend events</li></ul>	YES	YES
<b>Sponsorship agreements:</b>  TOVs made to the HCO for an	<ul style="list-style-type: none"><li>Congress sponsorship</li></ul>	N/A	YES

educational or scientific event.	<ul style="list-style-type: none"> <li>• Stand or booth space</li> <li>• Symposia</li> </ul>		
<b>Fees for Service:</b> Payments made to HCPs or HCOs in return for providing services or consultancy work, such as speaking engagements, participation in advisory boards, or training delivery.	<ul style="list-style-type: none"> <li>• Advisory board</li> <li>• Speaker engagements or services</li> <li>• Consultancy services</li> </ul>	YES	YES
<b>Related expenses to the fees for service contract:</b> Reimbursement of an HCP or HCO under the terms of a service contract for any additional costs incurred by an HCP or HCO while providing a contracted service or consultancy work	<ul style="list-style-type: none"> <li>• Travel (e.g. flight, train, taxi, car hire, tolls, mileage reimbursement, parking, shared ground transportation)</li> <li>• Accommodation</li> </ul>	YES	YES

## 2.6. Indirect ToVs

ABPI Transfer of Value Category	Example activities	HCP	HCO
<b>Contributions to Cost of Event - Travel and accommodation relating to a congress or educational event:</b> Payments to provider covering travel, lodging, and related expenses for healthcare professionals attending meetings, conferences, or third-party educational/ scientific meetings.	<ul style="list-style-type: none"> <li>• Travel (e.g. flight, train, taxi, car hires, tolls, mileage reimbursement, parking)</li> <li>• Accommodation</li> </ul>	YES	YES
<b>Contributions to Cost of Event - Registration fees:</b> TOVs related to the payment event organiser to registration of an HCP / HCO to attend a congress or educational event.	<ul style="list-style-type: none"> <li>• Registration fees paid for the HCP/HCO to attend events</li> </ul>	YES	YES
<b>Sponsorship agreements:</b> TOVs made to an event organiser or other third party appointed by the HCO to manage an educational or scientific event.	<ul style="list-style-type: none"> <li>• Congress sponsorship</li> <li>• Stand or booth space</li> <li>• Symposia</li> </ul>	N/A	YES
<b>Related expenses to the fees for service contract:</b> Payment to third party service provider for	<ul style="list-style-type: none"> <li>• Travel (e.g. flight, train, taxi, car hire, tolls, mileage reimbursement, parking, shared ground</li> </ul>	YES	YES

any additional costs incurred by an HCP or HCO while providing a contracted service or consultancy work	transportation) • Accommodation		
---	------------------------------------	--	--

## 2.7. Non-monetary ToVs

None

## 2.8. ToVs in case of partial attendances or cancellation and refund

None

## 2.9. Cross-border activities

Neurocrine UK Limited includes TOV to Recipients in the UK and other EFPIA countries. This includes all TOV made by Neurocrine UK Limited to Recipients in the European countries covered in the ABPI and EFPIA codes. Inclusion of Recipients in other EFPIA countries goes beyond the requirements of the ABPI code. This decision aligns with the disclosure methodology previously implemented by Neurocrine UK Limited in 2023 and 2024. During data year 2025 Neurocrine UK Limited is unable to disclose values separately for regions outside the UK because it lacked affiliates and presence in certain markets. Additionally, during data year 2025 Neurocrine UK Limited medicines were also marketed in other countries, for example the United States, Switzerland, Sweden, Denmark, Norway and Iceland by alliance partner pharmaceutical organisations who disclose ToVs as separate entities.

## 2.10. R&D

This disclosure includes ToVs to HCPs or HCOs related to the planning or conduct of:

- Clinical trials (as defined in Directive 2001/20/EC); or
- Non-interventional studies that are prospective in nature and that involve the collection of patient data from, or on behalf, of individual or groups of HCPs specifically for the study.

Example activities include: Clinical Trials; Data Monitoring Committees related to studies; Non-Interventional Studies that are prospective in nature; Investigators Initiated Research (IIR); Clinical & Research Collaborations and sample analyses.

## 2.11. Voluntary disclosure

Disclosure includes ToVs to Recipients in EFPIA countries covered by EFPIA codes. Inclusion of Recipients in other EFPIA countries goes beyond the requirements of the ABPI code. This decision aligns with the disclosure methodology previously implemented by Neurocrine UK Limited in 2023 and 2024.

## 3. Specific considerations

### 3.1. Country unique identifier

Country unique identifiers have not been used.

### 3.2. Self-incorporated HCP

Neurocrine UK Limited has reported ToVs made to HCPs with their own Limited company as

a payment made to the HCP.

### **3.3. Multi-year agreements**

Where contracts are valid for more than one year, each individual TOV is captured and disclosed in the reportable disclosure period.

### **3.4. Country specificities**

None used or applicable

### **3.5. Quality Checks**

Cross check payments to be made under the contracts with corresponding invoice and then payments actually made by accounting system. Final draft disclosure spreadsheet and accompanying documentation reviewed by relevant functional heads before submission.

## **4. Data protection legal basis**

### **4.1. Consent collection**

Neurocrine UK Limited obtains the consent, as required, of each HCP to disclose their personal data primarily via data protection, privacy, and disclosure clauses in contracts. Neurocrine UK Limited will disclose the total value of the TOVs for those HCPs and ORDMs who have given consent for individual disclosure. For those who do not provide consent or where consent is withdrawn, their TOVs will be included in an aggregated total, as required by the ABPI Code.

### **4.2. Legitimate interests**

This legal basis was not used in the data year 2025.

## **5. Form of disclosure**

### **5.1. Date of publication**

30/06/2026

### **5.2. Disclosure platform**

'Disclosure UK – [www.disclosureuk.org.uk](http://www.disclosureuk.org.uk)'

### **5.3 Disclosure language**

English

## **6. Disclosure financial data**

### **6.1 Currency**

Amounts are reported in UK sterling, where transfers of value were captured in other currencies, amounts were converted to UK sterling based on European Central Bank spot exchange rate on 31 December 2025.

## **6.2 VAT included or excluded**

Where applicable, transfers of value declared include the VAT applied at relevant levels in countries in which the payment was made. Cross border TOV or indirect TOV may or may not include VAT depending on the submitting source or country.

## **6.3 Calculation rules**

As no in-kind ToVs or other non-monetary values were provided, no calculation rules needed to be applied.

## **7. Additional Information**

### **7.1. Inquiries**

Neurocrine UK Limited will review and investigate any inquiries from HCPs and HCOs concerning the submitted transparency reports. Any modifications resulting from this review will be incorporated into an updated report, in accordance with ABPI guidelines.